Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients
- 1 March 2012
- journal article
- clinical trial
- Published by Elsevier BV in British Journal of Anaesthesia
- Vol. 108 (3), 460-468
- https://doi.org/10.1093/bja/aer441
Abstract
Dexmedetomidine is a highly selective and potent α(2)-adrenoceptor agonist registered for sedation of patients in intensive care units. There is little information on factors possibly affecting its pharmacokinetics during long drug infusions in critically ill patients. We characterized the pharmacokinetics of dexmedetomidine in critically ill patients during long-term sedation using a population pharmacokinetic approach. Twenty-one intensive care patients requiring sedation and mechanical ventilation received dexmedetomidine with a loading dose of 3-6 µg kg(-1) h(-1) in 10 min and a maintenance dose of 0.1-2.5 µg kg(-1) h(-1) for a median duration of 96 h (range, 20-571 h). Cardiac output (CO), laboratory and respiratory parameters, and dexmedetomidine concentrations in arterial plasma were measured. The pharmacokinetics was determined by population analysis using linear multicompartment models. The pharmacokinetics of dexmedetomidine was best described by a two-compartment model. The population values (95% confidence interval) for elimination clearance, inter-compartmental clearance, central volume of distribution, and volume of distribution at steady state were 57.0 (42.1, 65.6), 183 (157, 212) litre h(-1), 12.3 (7.6, 17.0), and 132 (96, 189) litre. Dexmedetomidine clearance decreased with decreasing CO and with increasing age, whereas its volume of distribution at steady state was increased in patients with low plasma albumin concentration. The population pharmacokinetics of dexmedetomidine was generally in line with results from previous studies. In elderly patients and in patients with hypoalbuminaemia, the elimination half-life and the context-sensitive half-time of dexmedetomidine were prolonged.Keywords
Funding Information
- Turku University Hospital Research Funds (13821)
This publication has 16 references indexed in Scilit:
- Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic conceptsBritish Journal of Anaesthesia, 2011
- Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patientsActa Anaesthesiologica Scandinavica, 2011
- Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unitCritical Care Medicine, 2010
- Effects of Low and High Plasma Concentrations of Dexmedetomidine on Myocardial Perfusion and Cardiac Function in Healthy Male SubjectsAnesthesiology, 2006
- National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and StratificationAnnals of Internal Medicine, 2003
- Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care †British Journal of Anaesthesia, 2002
- Postoperative Pharmacokinetics and Sympatholytic Effects of DexmedetomidineAnesthesia & Analgesia, 1997
- ALPHA 2 ADRENOCEPTOR AGONISTS AND ANAESTHESIABritish Journal of Anaesthesia, 1993
- Computer-controlled Infusion of Intravenous Dexmedetomidine Hydrochloride in Adult Human VolunteersAnesthesiology, 1993
- Context-sensitive Half-time in MulticompartmentAnesthesiology, 1992